National Institutes of Health
-
Drug and Digital Technologies Are Part of NIH’s Long Covid Clinical Trial Plans
Long Covid continues to afflict patients and mystify clinicians. The National Institutes of Health is trying to identify potential treatments and it is launching a series of clinical trials that will assess a wide range of therapeutic interventions.
-
NIH Marburg Vaccine Posts Encouraging Results in First-in-Human Study
Marburg virus has no FDA-approved vaccines or therapies, but a vaccine candidate from the National Institutes of Health now has encouraging results from a U.S. clinical trial. Next steps include tests in more countries including Ghana, where a Marburg outbreak was declared last summer.
-
Do you advise self-insured employers? You Can Help Us!
Take part in this survey and share some of the trends you are seeing among your clients across healthcare, including chronic conditions, behavioral health and navigation.
-
J&J HIV vaccine fails study in Africa, but a separate clinical trial continues in Europe, Americas
Johnson & Johnson reported results from a mid-stage study in southern Africa showing just 25% efficacy for its HIV vaccine. J&J developed the HIV vaccine with the same technology used in its successful Ebola and Covid-19 vaccines.
-
Clinical data quashes experimental Covid-19 therapies from Brii, Vir & Apellis
Antibody therapies from Brii Biosciences and Vir Biotechnology failed to show sufficient efficacy to advance to the next stage of an NIH-sponsored Covid-19 clinical trial. Apellis Pharmaceuticals and Durect also stopped work on experimental Covid treatments.
-
NIH panel contradicts FDA on authorization for convalescent plasma in Covid-19
The agency’s Covid-19 Treatment Guidelines Panel stated there was insufficient evidence for or against the treatment and pointed out that in certain groups, such as intubated patients, no benefit in seven-day overall survival was observed.
-
Report: FDA halted move to authorize convalescent plasma for Covid-19 over evidence concerns
The New York Times reported that the FDA was prepared to issue an emergency use authorization for the treatment last week, but NIH Director Francis Collins and NIAID Director Anthony Fauci intervened, arguing that data were too weak.
-
NIAID launches clinical trial network for preventive drugs, vaccines against Covid-19
The NIAID create the Covid-19 Prevention Trials Network by combining four existing ones, primarily focused on HIV and AIDS, which will continue that work in addition to their new focus on Covid-19.
-
Trump’s favorite drug for Covid-19 smacked down in VA study, NIH guidance
A preprint retrospective analysis among 368 patients hospitalized with Covid-19 in the VA system found no benefit and a higher degree of death from hydroxychloroquine. A panel of experts also recommended against using the drug with azithromycin outside of trials due to potential toxicity.
-
Our weekly cartoon: Federal agency therapy
Our weekly cartoon focuses on the National Institutes of Health.
-
Trayt Health Seeks to Increase Access to Diagnoses and Treatments
CEO Malekeh Amini explains how Trayt Health can bridge the gap for patients seeking neurological care.
-
Trump’s proposed NIH cuts show disregard for importance of basic research
It’s likely that many drugs Americans take for granted wouldn’t exist today if not for the NIH-funded basic research that enabled their discovery and development. Fortunately, generous funding for the NIH has long enjoyed bipartisan support in Congress.
-
NIH, Gates Foundation invest $200M to develop gene therapies for developing countries
The partnership will have a particular focus on therapies to treat sickle cell disease and HIV, with each party committing $100 million to the effort.
-
BioPharma, Diagnostics, Health Services
NIH research initiative All of Us funds Color Genomics as its genetic counseling service
The partnership builds on an existing relationship between All of Us and Color, which was chosen as one of three genome centers that are responsible for actual genotyping of patient samples.
-
Administration stops NIH scientists from obtaining fetal tissue, possibly threatening HIV research
Science magazine reported that the move put the brakes on a preclinical HIV study and follows the cancellation of a contract between the FDA and a California-based company that supplies fetal tissue for medical research.
-
NVIDIA expands AI radiology efforts with new software capabilities and partnerships
The company is hoping to boost the adoption of AI in medical imaging with new software development kits and deals with Ohio State University and the NIH.